Jefferies Group LLC purchased a new stake in Exelixis (NASDAQ:EXEL) during the 4th quarter, Holdings Channel reports. The fund purchased 23,902 shares of the biotechnology company’s stock, valued at approximately $727,000.
Other hedge funds also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC acquired a new position in Exelixis during the 3rd quarter worth approximately $120,000. Sigma Planning Corp acquired a new position in Exelixis during the 4th quarter worth approximately $208,000. American International Group Inc. acquired a new position in Exelixis during the 4th quarter worth approximately $208,000. Klingenstein Fields & Co. LLC acquired a new position in Exelixis during the 4th quarter worth approximately $213,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in Exelixis during the 3rd quarter worth approximately $236,000. Hedge funds and other institutional investors own 80.49% of the company’s stock.
In related news, Director Lance Willsey sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $23.91, for a total value of $717,300.00. Following the sale, the director now owns 483,273 shares of the company’s stock, valued at approximately $11,555,057.43. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Vincent T. Marchesi sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $24.73, for a total value of $370,950.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 120,029 shares of company stock worth $3,158,287. 5.10% of the stock is owned by corporate insiders.
Shares of Exelixis (NASDAQ EXEL) opened at $23.81 on Tuesday. The firm has a market capitalization of $7,301.01, a P/E ratio of 48.59, a P/E/G ratio of 1.34 and a beta of 1.96. Exelixis has a fifty-two week low of $18.03 and a fifty-two week high of $32.50.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.12. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The business had revenue of $120.10 million for the quarter, compared to analysts’ expectations of $120.25 million. During the same quarter in the prior year, the firm posted $0.12 EPS. The company’s revenue was up 54.8% compared to the same quarter last year. research analysts forecast that Exelixis will post 0.57 earnings per share for the current year.
EXEL has been the topic of several recent analyst reports. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target on the stock in a report on Tuesday, January 2nd. UBS upgraded Exelixis from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 27th. SunTrust Banks restated a “buy” rating and issued a $38.00 price target on shares of Exelixis in a report on Thursday, December 21st. Finally, Oppenheimer restated a “hold” rating on shares of Exelixis in a report on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $34.10.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thestockobserver.com/2018/03/20/jefferies-group-llc-purchases-shares-of-23902-exelixis-exel.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.